title: [Cost-effectiveness of quadrivalent vaccine against human papilloma virus in Argentina based on a dynamic transmission model].
abstract: OBJECTIVE
  To assess the cost-effectiveness of the quadrivalent vaccine against human papillomavirus (HPV) in Argentina from the health system perspective.
  
  
  METHODS
  A dynamic transmission model was used to estimate the impact of the vaccine on the incidence of cervical cancer, warts, and other HPV related diseases; in quality adjusted life years (QALYs); and in healthcare costs.
  
  
  RESULTS
  Vaccination could reduce the risk of cervical cancer by 60% and by 67% the risk of genital warts. Compared to a non-vaccine scenario, the immunization strategy showed an incremental benefit of 0.00234 QALY per person at an incremental cost of US$2.36, resulting in an incremental cost-effectiveness ratio of US$1007.55 per QALY gained. Sensitivity analysis proved the robustness of these results.
  
  
  CONCLUSIONS
  Immunization with the quadrivalent vaccine was a cost-effective intervention in Argentina, and it was far below the threshold of one gross domestic product per capita (US$15 009) per QALY gained.
authors.affiliation: Instituto de Efectividad Clínica y Sanitaria, Buenos Aires, Argentina.
authors.forename: Andrés
authors.initials: A
authors.lastname: Pichon-Riviere
authors.affiliation: Instituto de Efectividad Clínica y Sanitaria, Buenos Aires, Argentina.
authors.forename: Andrea
authors.initials: A
authors.lastname: Alcaraz
authors.affiliation: Instituto de Efectividad Clínica y Sanitaria, Buenos Aires, Argentina.
authors.forename: Joaquín
authors.initials: J
authors.lastname: Caporale
authors.affiliation: Instituto de Efectividad Clínica y Sanitaria, Buenos Aires, Argentina.
authors.forename: Ariel
authors.initials: A
authors.lastname: Bardach
authors.affiliation: Instituto de Efectividad Clínica y Sanitaria, Buenos Aires, Argentina.
authors.forename: Lucila
authors.initials: L
authors.lastname: Rey-Ares
authors.affiliation: Instituto de Efectividad Clínica y Sanitaria, Buenos Aires, Argentina.
authors.forename: Karen
authors.initials: K
authors.lastname: Klein
authors.affiliation: Instituto de Efectividad Clínica y Sanitaria, Buenos Aires, Argentina.
authors.forename: María
authors.initials: M
authors.lastname: Calderón
authors.affiliation: Instituto de Efectividad Clínica y Sanitaria, Buenos Aires, Argentina.
authors.forename: Federico
authors.initials: F
authors.lastname: Augustovski
authors.affiliation: Hospital de Clínicas, Buenos Aires, Argentina.
authors.forename: Silvio
authors.initials: S
authors.lastname: Tatti
mesh_terms: D001118:Argentina; D002648:Child; D003218:Condylomata Acuminata / Q000517:prevention & control* / Q000821:virology; D003362:Cost-Benefit Analysis; D005260:Female; D005833:Genital Neoplasms, Female / Q000517:prevention & control* / Q000821:virology; D059066:Gross Domestic Product; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / Q000191:economics*; D006801:Humans; D008962:Models, Theoretical; D030361:Papillomavirus Infections / Q000191:economics / Q000517:prevention & control* / Q000635:transmission; D019057:Quality-Adjusted Life Years; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control* / Q000821:virology; D014611:Vaccination / Q000191:economics*
chemical_list: D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18